BMS-986458
PreclinicalSmall molecule
Bristol-Myers SquibbBMS-986458 is one of 5 small molecule programs targeting Relapsed/Refractory Non-Hodgkin Lymphoma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Relapsed/refractory Non-Hodgkin Lymphoma
#DrugCompanyPhaseTrials
1Rituxan
RochePreclinical
LUNSUMIO
RochePreclinical
Epkinly
GenmabPreclinical
Golcadomide
Bristol-Myers SquibbPreclinical
BMS-986458
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Relapsed/Refractory Non-Hodgkin Lymphoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BMS-986458. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company